InvestorsHub Logo
Followers 0
Posts 4
Boards Moderated 0
Alias Born 01/10/2020

Re: None

Tuesday, 06/23/2020 3:02:47 PM

Tuesday, June 23, 2020 3:02:47 PM

Post# of 3707
Palatin is behind the competition.

Swedish SynAct Pharma (https://markets.businessinsider.com/stocks/synact_pharma-stock) will launch their phase II-study in ARDS/COVID-19 in Q3 this year. An orphan drug designation will be filed soon as well with the FDA.

SynAct also targets the melanocortin system, orally and without side effects. The founders sold their previous company to Abbvie/Abbott, go figure what will happen to SynAct ;)

Will be a tough battle for Palatin.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PTN News